168 related articles for article (PubMed ID: 28885307)
1. The treatment of paraprotein-related kidney disease.
Hutchison CA; Xiong F; Mollee P
Curr Opin Nephrol Hypertens; 2017 Nov; 26(6):477-483. PubMed ID: 28885307
[TBL] [Abstract][Full Text] [Related]
2. Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.
Finkel KW; Cohen EP; Shirali A; Abudayyeh A;
Clin J Am Soc Nephrol; 2016 Dec; 11(12):2273-2279. PubMed ID: 27526708
[TBL] [Abstract][Full Text] [Related]
3. Extracorporeal Removal of Light Chains: New Data and Continued Controversies.
Finkel KW; Gallieni M
Clin J Am Soc Nephrol; 2018 Nov; 13(11):1753-1754. PubMed ID: 30348812
[No Abstract] [Full Text] [Related]
4. Rapid Deterioration of the Renal Function Caused by the Coexistence of Intratubular Amyloidosis and Myeloma Cast Nephropathy.
Kato H; Fujigaki Y; Asakawa S; Yamaguchi Y; Uozaki H; Komatsuda A; Nagata M; Uchida S
Intern Med; 2015; 54(23):3023-8. PubMed ID: 26631886
[TBL] [Abstract][Full Text] [Related]
5. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
[TBL] [Abstract][Full Text] [Related]
6. [Improved prognosis in light chain nephropathy due to multiple myeloma].
Juul JS; Larsen T; Marcussen N; Pedersen EB
Ugeskr Laeger; 2012 Apr; 174(17):1159-60. PubMed ID: 22533933
[TBL] [Abstract][Full Text] [Related]
7. A pharmacist's review of the treatment of systemic light chain amyloidosis.
Hughes DM; Staron A; Sanchorawala V
J Oncol Pharm Pract; 2021 Jan; 27(1):187-198. PubMed ID: 33028132
[TBL] [Abstract][Full Text] [Related]
8. [Update in multiple myeloma: international criteria for treatment response and renal complications].
Decaux O; Karras A
Rev Med Interne; 2009 Dec; 30(12):1080-3. PubMed ID: 19833418
[No Abstract] [Full Text] [Related]
9. [Renal disease in multiple myeloma].
Hiromura K; Nojima Y
Nihon Rinsho; 2007 Dec; 65(12):2229-34. PubMed ID: 18069265
[TBL] [Abstract][Full Text] [Related]
10. The radical treatment of paraprotein disorders affecting the kidney.
Peniket AJ; Littlewood TJ; Winearls CG
Nephrol Dial Transplant; 2003 Aug; 18(8):1431-4. PubMed ID: 12897075
[No Abstract] [Full Text] [Related]
11. Management options for cast nephropathy in multiple myeloma.
Cockwell P; Hutchison CA
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
[TBL] [Abstract][Full Text] [Related]
12. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
Rezk T; Lachmann HJ; Fontana M; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Bass P; Hawkins PN; Gillmore JD
Kidney Int; 2017 Dec; 92(6):1476-1483. PubMed ID: 28729034
[TBL] [Abstract][Full Text] [Related]
13. Reversible acute kidney injury (AKI) by active removal of serum light chains in an HIV positive patient with myeloma kidney.
Sowole L; Burns A; Kaur B; Davenport A
Clin Nephrol; 2011 Nov; 76(5):417-20. PubMed ID: 22000564
[TBL] [Abstract][Full Text] [Related]
14. The use of different dialysis membranes in therapy of patients with multiple myeloma.
Szymczak M; Zielińska D; Musiała A
Polim Med; 2019; 49(2):67-70. PubMed ID: 32544311
[TBL] [Abstract][Full Text] [Related]
15. Optimizing treatment strategies in myeloma cast nephropathy: rationale for a randomized prospective trial.
Bridoux F; Fermand JP
Adv Chronic Kidney Dis; 2012 Sep; 19(5):333-41. PubMed ID: 22920644
[TBL] [Abstract][Full Text] [Related]
16. Elevation of Plasmin-α2-plasmin Inhibitor Complex Predicts the Diagnosis of Systemic AL Amyloidosis in Patients with Monoclonal Protein.
Ishiguro K; Hayashi T; Yokoyama Y; Aoki Y; Onodera K; Ikeda H; Ishida T; Nakase H
Intern Med; 2018 Mar; 57(6):783-788. PubMed ID: 29021469
[TBL] [Abstract][Full Text] [Related]
17. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury.
Heyne N; Denecke B; Guthoff M; Oehrlein K; Kanz L; Häring HU; Weisel KC
Ann Hematol; 2012 May; 91(5):729-735. PubMed ID: 22170517
[TBL] [Abstract][Full Text] [Related]
18. Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.
Martín-Reyes G; Toledo-Rojas R; Torres-de Rueda Á; Sola-Moyano E; Blanca-Martos L; Fuentes-Sánchez L; Martínez-Esteban MD; Díez-de los Ríos MJ; Bailén-García A; González-Molina M; García-González I
Nefrologia; 2012; 32(1):35-43. PubMed ID: 22294003
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma with extensive AL amyloidosis presenting as chronic diarrhoea.
Kogler W; Canha C; Makary R; Omman R; Isache CL
BMJ Case Rep; 2020 Jan; 13(1):. PubMed ID: 31919068
[TBL] [Abstract][Full Text] [Related]
20. Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
Tan J; Lam-Po-Tang M; Hutchison CA; de Zoysa JR
Nephrology (Carlton); 2014 Jul; 19(7):432-5. PubMed ID: 24931113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
